The preparatory meeting for the first meeting of the R&D and Transformation Service Professional Committee of the China Food and Drug Enterprise Quality and Safety Promotion Association was successfully held in Beijing on August 5th. Guanhua Du, Deputy Dean of the Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College; Chao,Liu Secretary-General of the Chinese Society of Toxicology; Lijian Zhang, Chief Physician of Thoracic Surgery, Peking University Cancer Hospital; Dong Wu, Deputy Chief Physician, Department of Gastroenterology, Peking Union Medical College Hospital; Beijing Chest Hospital Jian Tian, Director of the Office of the Center for Translational Medicine, Zhenwen Chen, Professor of the Department of Zoology, Capital Medical University School of Basic Medicine, Dr. Jiangzeng Cheng, founder of Tongxueyi, Dr. Qiang Guo, Senior Engineer of the Chinese Academy of Sciences, Rui Zhu, Deputy Director of the Zhongguancun Medical Engineering Transformation Center, and Zhongguancun Medical Engineering Transformation Center International Kun Cao, project director, and representatives from Beijing New Leading and other companies attended the meeting and had in-depth exchanges

In the meeting, Director Rui Zhu introduced the background and work objectives of the special committee to the experts and business leaders, and emphasized that the purpose of the special committee is to integrate the resources of the national medicine and health industry, and give full play to the government, enterprises, scientific research institutes and the role of a bridge and a link between enterprises, enterprises and enterprises, to carry out the first trial of policies that are conducive to the industry’s technological innovation and achievement transformation, and to promote the industry’s high-quality and high-end development. The government explores innovative development practices at the top and the industry at the bottom. Upstream and downstream services.
 

GuanhuaDu, Dean of the Institute of Pharmaceutical Research of the Chinese Academy of Medical Sciences and Peking Union Medical College, said that the establishment of the special committee is accurate, and there are many tasks to be undertaken, especially the professionalization, informationization and knowledge of personnel training. The special committee needs to ask more Small and medium-sized enterprises convey government and policy information, coordinate with all parties to be standard setters, and play an exemplary and leading role.

Lijian Zhang, director of the Department of Thoracic Surgery of Peking University Cancer Hospital, said that 2020 is entering the late stage of the new crown epidemic. At this time, the establishment of a special committee must create a new atmosphere and become a new style of indomitable association. Solve problems pragmatically.
 

Subsequently, the leaders of the conference expressed their views on the establishment and development plan of the special committee. It is generally said that the special committee should help enterprises to enhance their competitiveness. First, they need the participation of clinicians and clinical experts to guide enterprises to make standards, modernization is a weapon to promote the development of enterprises, and modernization must be deepened into the pores, from personnel to management. In the end, everyone pointed out that the introduction of the new policy is the most difficult to transform services. For example, during the epidemic, nucleic acid testing has been popularized. In many cases, startups are often at a stage where they do not understand the policy, so the special committee can use its own advantages , Provide policy counseling for small and medium-sized enterprises and promote enterprise development.
 

The Executive Council of the Promotion Council appointed Ms.ShijingGao, President of Beijing New Leading Pharmaceutical Technology Development Co., Ltd., as the vice chairman. New Leading Pharmaceuticals is the vice chairman unit of the R&D and Transformation Service Professional Committee of the China Food and Drug Enterprise Quality Safety Promotion Association. Director Zhu Rui of the committee issued a letter of appointment to Ms. Gao.

Ms Gao said that as a socially responsible pharmaceutical company, New Leading always pays attention to the quality and safety of food and drugs in my country. As the initiator of the R&D and Transformation Service Professional Committee of the China Food and Drug Enterprise Quality and Safety Promotion Association, we will actively assume the responsibility of R&D and transformation services, adhering to the spirit of the experts participating in the meeting of the results of the database are transformed into the information database to truly bridge the gap between government and enterprises and research units, and strive to become a leading enterprise in the industry. New Leading’s vision of “It’s me who keeps China’s new drug technology and production process in sync with the world coincides with the purpose of the special committee. New Leading is willing to develop together with the special committee to provide more member units with tangible services. Actively work hard to promote the construction and operation of special committees, and promote food and drug quality and safety and industry development.

In 2020, New Leading relies on the existing technology and management team, integrates the Zhengzhou linkong Biomedical Industrial Park platform, and creates the "New Leading CXO" whole industry chain service system, which gathers R&D, clinical, industrial and expert resources, and is able to serve the enterprise Provide one-stop service for the whole process!
 

Accelerate the transformation of innovation achievements, theNew leading is already in action.I believe that the establishment of the R&D and Transformation Service Professional Committee of the China Food and Drug Enterprise Quality and Safety Promotion Association will bring new help to the enterprise!